Day: November 8, 2022

Agreement includes aggregate upfront and target nomination fees of up to $21.5 million for up to 6 targets, and additional R&D and sales milestones plus tier-based mid-single to low double-digit royalties.

Abu Dhabi, Nov. 08, 2022 (GLOBE NEWSWIRE) — Insilico Medicine, a clinical stage artificial intelligence (AI)-driven drug discovery company, announced a multi-year, multi-target strategic research collaboration with Sanofi. Under the terms of the agreement, the collaboration will leverage Insilico Medicine’s AI platform, Pharma.AI, to advance drug development candidates for up to six new targets.

“We look forward to working with Insilico Medicine, a demonstrated leader in AI-powered drug discovery,” said Changchun Xiao, Head of China Research at Sanofi.  “This collaboration will leverage our complementary capabilities, as well as the co-location of our scientific teams, to boost the drug discovery efforts of the Sanofi Institute for Biomedical Research (SIBR), Sanofi’s R&D center in China.”

Under the terms of the agreement, Sanofi will pay Insilico Medicine a total of up to $21.5 million covering the upfront and target nomination fees to benefit from Insilico’s end-to-end Pharma.AI platform and gain access to a team of interdisciplinary drug discovery scientists to identify, synthesize, and advance high-quality lead therapeutic compounds up to development candidate stage. Additional payments will be made if key research, development, and sales milestones are met, and could total up to $1.2 billion. The collaboration also establishes mid-single to up to low double-digit tiered royalties for any products developed.

“We are very happy to collaborate with Sanofi, a company with a clear strategy in AI-powered drug discovery,” said Alex Zhavoronkov, PhD, CEO and founder of Insilico Medicine. “This close collaboration will allow Sanofi to immediately gain the capabilities of one of the top AI startups in addition to enriching their drug discovery pipeline.”

“We are thrilled to collaborate with Sanofi. Leveraging Sanofi’s strong drug research and development expertise and Insilico’s powerful AI platform, we believe we can accelerate novel therapeutics discovery to address diseases with unmet medical needs,” said Feng Ren, PhD, co-CEO and Chief Scientific Officer of Insilico Medicine. “Together we will use cutting-edge AI technologies to make significant breakthroughs in drug R&D.”

About Insilico Medicine

Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and to design novel molecular structures with desired properties. Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system (CNS) diseases and aging-related diseases.

For more information, visit www.insilico.com

For media inquiries, contact media@insilicomedicine.com

Attachment

• Advancing AI Drug Discovery

Polina Firsanova
Insilico Medicine
420-641-6266
polly.firs@insilicomedicine.com

GlobeNewswire Distribution ID 8691820

For gift giving, collecting, or every day enjoyment new calendar features some of Europe’s finest producers and covers the remainder of 2022

Crurated Barrels November and December Calendar

Just In Time For The Holidays Crurated Announces More Fractional Barrel Auctions Backed by NFT Technology With Winemakers Across France and Italy. For gift giving, collecting, or every day enjoyment new calendar features some of Europe’s finest producers and covers the remainder of 2022

LONDON, Nov. 08, 2022 (GLOBE NEWSWIRE) —  With the holiday and gift giving season right around the corner, Crurated, a blockchain and member-based wine community, has released a new barrel auction calendar for the remainder of 2022. The offering features some of the finest winemakers from France and Italy and extends the fractional barrel sales after a successful first round of auctions. The recently announced program allows Crurated members to purchase fractions of barrels that are certified through blockchain and NFT technology.

The offering also gives buyers the ability to customize bottle formats and labels for the gift recipient or themselves. Many of the producers on the platform rarely or never make larger format bottles even though collectors and buyers often ask for them. Fractional barrels now allow producers to determine the exact number and sizes of bottles that are needed. In many cases, the only way to have larger formats for the wines being auctioned is exclusively through Crurated.

The next round of fractional barrel auctions include:

• Domaine Gerorges Mugneret-Gibourg — November 7-13
  • Vosne-Romanée “La Colombière” 2021
  • Chambolle-Musigny 1er Cru “Les Feusselottes” Cuvée Augustin 2021
  • Ruchottes-Chambertin Grand Cru 2021

• Domaine Pierre Girardin — November 14-20
  • Échezeaux Grand Cru 2021
  • Bonnes-Mares Grand Cru 2021
  • Griotte-Chambertin Grand Cru 2021
  • Richebourg Grand Cru 2021
• Montevertine — November 21-27
  • Le Pergole Torte 2020

• Domaine Y. Clerget — December 5-11
  • Clos de Vougeot Grand Cru 2021
  • Volnay 1er Cru Clos du Verseuil 2021
  • Pommard 1er Cru Les Rugiens 2021

• Domaine Hubert Lignier — December 12-18
  • Clos de la Roche Grand Cru Bio 2021
  • Morey Saint-Denis 1er Cru Vieilles Vignes Bio 2021
  • Morey-Saint-Denis Trilogie Bio 2021
  • Bourgogne Pinot Noir Grand Chaliot 2021
• Domaine Bruno Colin — December 19-25
  • Corton-Charlemagne Grand Cru 2021

“When we launched barrel sales, we knew what we were offering our members was unique. Little did we know that barrels would sell out so quickly and in some cases within 24 hours,” said Alfonso de Gaetano, founder of Crurated. “Our team is pleased to be announcing a new slate of auctions with some of Europe’s most sought-after wines and just in time for the holidays.”

About Crurated
Launched in 2021 with an emphasis on France and Italy, Crurated is a membership-based wine community designed to connect connoisseurs directly with world-class producers. A team of specialists provides personalized services and authentic experiences, while Crurated’s seamless logistics service guarantees quality and provenance thanks to secure wine cellar storage and innovative blockchain technology. For more on Crurated, visit crurated.com.

Michael Volpatt
michael@larkinvolpatt.com
415 994 8864

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ee03a3c2-35fd-4334-9adb-d2f8c7c2a7e9

A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c848d052-fe03-4cdb-becd-c00e6a4cdb57

GlobeNewswire Distribution ID 8691599